Squarepoint
PCVX icon

Squarepoint’s Vaxcyte PCVX Stock Holding History

Squarepoint’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,862
Closed -$483K – 4828
2025
Q2 		$483K Sell
14,862
-330,020
-96% -$10.8M ﹤0.01% 3313
2025
Q1 		$13M Sell
344,882
-31,964
-8% -$2.56M 0.02% 901
2024
Q4 		$30.8M Buy
376,846
+313,354
+494% +$31.1M 0.03% 561
2024
Q3 		$7.26M Buy
63,492
+40,136
+172% +$3.62M 0.01% 1166
2024
Q2 		$1.76M Buy
+23,356
New +$1.59M ﹤0.01% 2143
2023
Q3 		– Sell
-5,140
Closed -$257K – 4120
2023
Q2 		$257K Sell
5,140
-20,029
-80% -$949K ﹤0.01% 3063
2023
Q1 		$943K Sell
25,169
-3,874
-13% -$164K ﹤0.01% 1936
2022
Q4 		$1.39M Buy
29,043
+20,000
+221% +$785K 0.01% 1595
2022
Q3 		$217K Buy
+9,043
New +$229K ﹤0.01% 2649
2021
Q3 		– Sell
-16,504
Closed -$372K – 3303
2021
Q2 		$372K Buy
+16,504
New +$338K ﹤0.01% 2370
2021
Q1 		– Sell
-11,233
Closed -$298K – 3498
2020
Q4 		$298K Buy
+11,233
New +$418K ﹤0.01% 2207

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Squarepoint's PCVX Position: Q3 2025 in Review

Squarepoint sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 14,862 shares — an estimated $483K sold.

Squarepoint first reported a position in PCVX in Q4 2020 and held it in 11 quarters. The position peaked at $30.8M in Q4 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Squarepoint reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 14,862 Vaxcyte shares in Q3 2025, an estimated $483K.
  • Squarepoint first reported a position in Vaxcyte in Q4 2020 and held it in 11 quarters.
  • Squarepoint's Vaxcyte position peaked at $30.8M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.